[ad_1]
AstraZeneca reaffirms the “quality, safety and efficacy” of its covid vaccine and, in particular, of the batch that has ended up in the limelight for reporting serious adverse events. “Following the recent report of some serious adverse events reported in temporary concomitance with the administration of the AstraZeneca vaccine against Covid-19, the Company is collaborating with the health and regulatory authorities who are carrying out the necessary investigations,” the company announced.
“From an analysis of our safety data from more than 10 million administrations, there was no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any age group, sex, lot, or in any country where the vaccine has been used. AstraZeneca against Covid-19. The number of these events is significantly lower in vaccinated subjects than the number observed in the general population, “says AstraZeneca. The company “also intends to clarify that the quality controls carried out internally as a result of the Aifa report did not highlight any aspect that could have had an impact on the quality, safety, efficacy of the batch in question and the company was promptly informed of this. “. Aifa “.
[ad_2]
